Similarly, CXCL12 level was 1.8 ± 9.7 ng/ml in sera from naïve mice (Fig. 3E, yellow), increased to 18.4 ± 6.4 ng/ml in tumor-bearing mice (p < 1 × 10−6, Fig. 3E, blue), remained high at 17.1 ± 6.3 ng/ml in vehicle-treated mice (p < 1 × 10−6, Fig. 3E, red), dropped to 4.1 ± 2.1 ng/ml in imatinib-treated mice (p < 1 × 10−6, Fig. 3E, brown). Here, CXCL12 is linked to neoplasm.